BRIEF: Hutchmed’s revenue falls in first half of 2025

Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for its other major products. The company’s half-year profit rose sharply thanks to a one-time gain.

Hutchmed reported revenue of $277.7 million yuan for the six-month period, down 9% from the $305.7 million yuan it generated a year earlier, according to its results released last Thursday. Revenue from the company’s sales of Fruzaqla, its best-selling drug for treatment of colorectal cancer, rose 1% year-on-year to $43 million in the first half of the year. But that wasn’t enough to offset declines of 27% to 50% for its next three best-selling drugs.

The company’s net income jumped to $455 million in the first half of the year from $25.8 million a year earlier, benefiting from a $477 million one-time gain on disposal of an asset.

Hutchmed’s New York-listed stock fell 16.3% in the two trading days after the announcement to close last Friday at $15. The stock is up 4.5% this year.

By Doug Young

To subscribe to Bamboo Works weekly free newsletter, click here